{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:56:12Z","timestamp":1793386572274,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04936-3","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:20:03Z","timestamp":1786011603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4"],"prefix":"10.1007","volume":"96","author":[{"given":"Yucheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8458-7071","authenticated-orcid":false,"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"issue":"3","key":"4936_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"4936_CR2","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.3390\/cancers14071732","volume":"14","author":"HM Sanower","year":"2022","unstructured":"Sanower HM, Hidayah K, Abdulrahman JA, Zannat U, Jiun OD, Akbar J, Chee LY, Kaderi KKM, MAK M, Chiau ML, Wen GK, Abdul HM (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14(7):1732\u20131732. https:\/\/doi.org\/10.3390\/cancers14071732","journal-title":"Cancers"},{"key":"4936_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071732","author":"MS Hossain","year":"2022","unstructured":"Hossain MS, Karuniawati H, Jairoun AA, Urbi Z, Ooi J, John A, Lim YC, Kibria KMK, Mohiuddin AKM, Ming LC, Goh KW, Hadi MA (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14071732","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4936_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3322\/caac.21349","volume":"66","author":"KD Miller","year":"2016","unstructured":"Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66(4):271\u2013289. https:\/\/doi.org\/10.3322\/caac.21349","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"4936_CR5","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/path.1706","volume":"205","author":"DB Longley","year":"2005","unstructured":"Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275\u2013292. https:\/\/doi.org\/10.1002\/path.1706","journal-title":"J Pathol"},{"issue":"1","key":"4936_CR6","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","volume":"149","author":"CV Dang","year":"2012","unstructured":"Dang CV (2012) MYC on the path to cancer. Cell 149(1):22\u201335. https:\/\/doi.org\/10.1016\/j.cell.2012.03.003","journal-title":"Cell"},{"issue":"6","key":"4936_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/genes8060158","volume":"8","author":"A Kumari","year":"2017","unstructured":"Kumari A, Folk WP, Sakamuro D (2017) The dual roles of MYC in genomic instability and cancer chemoresistance. Genes (Basel) 8(6):158. https:\/\/doi.org\/10.3390\/genes8060158","journal-title":"Genes (Basel)"},{"issue":"7","key":"4936_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41419-024-06918-w","volume":"15","author":"Z Lei","year":"2024","unstructured":"Lei Z, Zhu Z, Yao Z, Dai X, Dong Y, Chen B, Wang S, Wang S, Bentum-Ennin L, Jin L, Gu H, Hu W (2024) Reciprocal interactions between lncRNAs and MYC in colorectal cancer: partners in crime. Cell Death Dis 15(7):539. https:\/\/doi.org\/10.1038\/s41419-024-06918-w","journal-title":"Cell Death Dis"},{"issue":"1","key":"4936_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02873-0","volume":"43","author":"X Zhu","year":"2024","unstructured":"Zhu X, Li C, Gao Y, Zhang Q, Wang T, Zhou H, Bu F, Chen J, Mao X, He Y, Wu K, Li N, Luo H (2024) The feedback loop of EFTUD2\/c-MYC impedes chemotherapeutic efficacy by enhancing EFTUD2 transcription and stabilizing c-MYC protein in colorectal cancer. J Exp Clin Cancer Res CR 43(1):7. https:\/\/doi.org\/10.1186\/s13046-023-02873-0","journal-title":"J Exp Clin Cancer Res CR"},{"issue":"5","key":"4936_CR10","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.7150\/thno.37621","volume":"10","author":"W Sun","year":"2020","unstructured":"Sun W, Li J, Zhou L, Han J, Liu R, Zhang H, Ning T, Gao Z, Liu B, Chen X, Ba Y (2020) The c-Myc\/miR-27b-3p\/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Theranostics 10(5):1981\u20131996. https:\/\/doi.org\/10.7150\/thno.37621","journal-title":"Theranostics"},{"key":"4936_CR11","doi-asserted-by":"publisher","first-page":"6855","DOI":"10.2147\/cmar.S207167","volume":"11","author":"Y Sun","year":"2019","unstructured":"Sun Y, Lai X, Yu Y, Li J, Cao L, Lin W, Huang C, Liao J, Chen W, Li C, Yang C, Ying M, Chen Q, Ye Y (2019) Inhibitor of DNA binding 1 (Id1) mediates stemness of colorectal cancer cells through the Id1-c-Myc-PLAC8 axis via the Wnt\/\u03b2-catenin and Shh signaling pathways. Cancer Manag Res 11:6855\u20136869. https:\/\/doi.org\/10.2147\/cmar.S207167","journal-title":"Cancer Manag Res"},{"issue":"3","key":"4936_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.apsb.2022.10.002","volume":"13","author":"L Zhang","year":"2023","unstructured":"Zhang L, Ye B, Chen Z, Chen ZS (2023) Progress in the studies on the molecular mechanisms associated with multidrug resistance in cancers. Acta Pharm Sin B 13(3):982\u2013997. https:\/\/doi.org\/10.1016\/j.apsb.2022.10.002","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"4936_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","volume":"22","author":"G Lei","year":"2022","unstructured":"Lei G, Zhuang L, Gan B (2022) Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer 22(7):381\u2013396. https:\/\/doi.org\/10.1038\/s41568-022-00459-0","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"4936_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, Sun B, Wang G (2020) Ferroptosis: past, present and future. Cell Death Dis 11(2):88. https:\/\/doi.org\/10.1038\/s41419-020-2298-2","journal-title":"Cell Death Dis"},{"issue":"1","key":"4936_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","volume":"21","author":"C Zhang","year":"2022","unstructured":"Zhang C, Liu X, Jin S, Chen Y, Guo R (2022) Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 21(1):47. https:\/\/doi.org\/10.1186\/s12943-022-01530-y","journal-title":"Mol Cancer"},{"issue":"18","key":"4936_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e37613","volume":"10","author":"S Zhong","year":"2024","unstructured":"Zhong S, Wang Z, Yang J, Jiang D, Wang K (2024) Ferroptosis-related oxaliplatin resistance in multiple cancers: potential roles and therapeutic implications. Heliyon 10(18):e37613. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e37613","journal-title":"Heliyon"},{"issue":"5","key":"4936_CR17","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1016\/j.bbagen.2012.11.020","volume":"1830","author":"R Brigelius-Floh\u00e9","year":"2013","unstructured":"Brigelius-Floh\u00e9 R, Maiorino M (2013) Glutathione peroxidases. Biochim Biophys Acta 1830(5):3289\u20133303. https:\/\/doi.org\/10.1016\/j.bbagen.2012.11.020","journal-title":"Biochim Biophys Acta"},{"key":"4936_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.freeradbiomed.2018.09.014","volume":"133","author":"TM Seibt","year":"2019","unstructured":"Seibt TM, Proneth B, Conrad M (2019) Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med 133:144\u2013152. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.09.014","journal-title":"Free Radic Biol Med"},{"key":"4936_CR19","doi-asserted-by":"publisher","first-page":"116512","DOI":"10.1016\/j.biopha.2024.116512","volume":"174","author":"W Zhang","year":"2024","unstructured":"Zhang W, Liu Y, Liao Y, Zhu C, Zou Z (2024) GPX4, ferroptosis, and diseases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 174:116512","journal-title":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"key":"4936_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.10308","author":"JD Mancias","year":"2015","unstructured":"Mancias JD, Pontano Vaites L, Nissim S, Biancur DE, Kim AJ, Wang X, Liu Y, Goessling W, Kimmelman AC, Harper JW (2015) Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife. https:\/\/doi.org\/10.7554\/eLife.10308","journal-title":"Elife"},{"key":"4936_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103360","volume":"77","author":"Y Deng","year":"2024","unstructured":"Deng Y, Zeng L, Liu H, Zuo A, Zhou J, Yang Y, You Y, Zhou X, Peng B, Lu H, Ji S, Wang M, Lai Y, Kwan HY, Sun X, Wang Q, Zhao X (2024) Silibinin attenuates ferroptosis in acute kidney injury by targeting FTH1. Redox Biol 77:103360. https:\/\/doi.org\/10.1016\/j.redox.2024.103360","journal-title":"Redox Biol"},{"issue":"9","key":"4936_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/cr.2016.95","volume":"26","author":"M Gao","year":"2016","unstructured":"Gao M, Monian P, Pan Q, Zhang W, Xiang J, Jiang X (2016) Ferroptosis is an autophagic cell death process. Cell Res 26(9):1021\u20131032. https:\/\/doi.org\/10.1038\/cr.2016.95","journal-title":"Cell Res"},{"issue":"5","key":"4936_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115701","volume":"44","author":"Z Wang","year":"2025","unstructured":"Wang Z, Di Y, Ye L, Fang W, Wen X, Zhang X, Qin J, Wang Y, Hu K, Zhu Z, He W, Chen Y (2025) NANS suppresses NF-\u03baB signaling to promote ferroptosis by perturbing iron homeostasis. Cell Rep 44(5):115701. https:\/\/doi.org\/10.1016\/j.celrep.2025.115701","journal-title":"Cell Rep"},{"issue":"1","key":"4936_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12943-023-01875-y","volume":"22","author":"Y Yang","year":"2023","unstructured":"Yang Y, Zhang J, Zhang W, Wang Y, Zhai Y, Li Y, Li W, Chang J, Zhao X, Huang M, Geng Q, Yang Y, Gong Z, Yu N, Shen W, Li Q, Huang S, Guo W (2023) A liquid biopsy signature of circulating extracellular vesicles-derived RNAs predicts response to first line chemotherapy in patients with metastatic colorectal cancer. Mol Cancer 22(1):199. https:\/\/doi.org\/10.1186\/s12943-023-01875-y","journal-title":"Mol Cancer"},{"issue":"1","key":"4936_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12943-023-01801-2","volume":"22","author":"Y Wu","year":"2023","unstructured":"Wu Y, Song Y, Wang R, Wang T (2023) Molecular mechanisms of tumor resistance to radiotherapy. Mol Cancer 22(1):96. https:\/\/doi.org\/10.1186\/s12943-023-01801-2","journal-title":"Mol Cancer"},{"issue":"3","key":"4936_CR26","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/jco.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, Benson AB 3rd, Cercek A, Cho M, Ciombor KK, Cremolini C, Davis A, Deming DA, Fakih MG, Gholami S, Hong TS, Jaiyesimi I, Klute K, Lieu C, Sanoff H, Strickler JH, White S, Willis JA, Eng C (2023) Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol 41(3):678\u2013700. https:\/\/doi.org\/10.1200\/jco.22.01690","journal-title":"J Clin Oncol"},{"key":"4936_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121827","volume":"290","author":"CZ Huang","year":"2022","unstructured":"Huang CZ, Zhou Y, Tong QS, Duan QJ, Zhang Q, Du JZ, Yao XQ (2022) Precision medicine-guided co-delivery of ASPN siRNA and oxaliplatin by nanoparticles to overcome chemoresistance of colorectal cancer. Biomaterials 290:121827. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121827","journal-title":"Biomaterials"},{"issue":"1","key":"4936_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01291-6","volume":"20","author":"SK Madden","year":"2021","unstructured":"Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM (2021) Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer 20(1):3. https:\/\/doi.org\/10.1186\/s12943-020-01291-6","journal-title":"Mol Cancer"},{"issue":"166","key":"4936_CR29","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2001556","volume":"4","author":"S Pyndiah","year":"2011","unstructured":"Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D (2011) c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal 4(166):ra19. https:\/\/doi.org\/10.1126\/scisignal.2001556","journal-title":"Sci Signal"},{"issue":"5","key":"4936_CR30","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bjc.1996.105","volume":"73","author":"TL Walker","year":"1996","unstructured":"Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE (1996) Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 73(5):610\u2013614. https:\/\/doi.org\/10.1038\/bjc.1996.105","journal-title":"Br J Cancer"},{"issue":"49","key":"4936_CR31","doi-asserted-by":"publisher","first-page":"80888","DOI":"10.18632\/oncotarget.13105","volume":"7","author":"Y Yu","year":"2016","unstructured":"Yu Y, Guo M, Wei Y, Yu S, Li H, Wang Y, Xu X, Cui Y, Tian J, Liang L, Peng K, Liu T (2016) FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc. Oncotarget 7(49):80888\u201380900. https:\/\/doi.org\/10.18632\/oncotarget.13105","journal-title":"Oncotarget"},{"issue":"17\u201318","key":"4936_CR32","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1101\/gad.327056.119","volume":"33","author":"Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Department of Biochemistry UoTSMC, Dallas, Texas 75390, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Koch Institute for Integrative Cancer Research DoB, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Lydia Hill Department of Bioinformatics UoTSMC, Dallas, Texas 75390, USA., Children's Medical Center Research Institute UoTSMC, Dallas, Texas 75390, USA., Children's Medical Center Research Institute UoTSMC, Dallas, Texas 75390, USA., Department of Pediatrics UoTSMC, Dallas, Texas 75390, USA., Nikolaus-Fiebiger-Center for Molecular Medicine UE-N, Erlangen 91054, Germany., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Harold C. Simmons Comprehensive Cancer Center UoTSMC, Dallas, Texas 75390, USA., Children's Medical Center Research Institute UoTSMC, Dallas, Texas 75390, USA., Howard Hughes Medical Institute D, Texas 75390, USA., Department of Biochemistry UoTSMC, Dallas, Texas 75390, USA., Koch Institute for Integrative Cancer Research DoB, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA., Department of Pathology MGHB, Harvard Medical School, Boston, Massachusetts 02114, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Harold C. Simmons Comprehensive Cancer Center UoTSMC, Dallas, Texas 75390, USA","year":"2019","unstructured":"Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Department of Biochemistry UoTSMC, Dallas, Texas 75390, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Koch Institute for Integrative Cancer Research DoB, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Lydia Hill Department of Bioinformatics UoTSMC, Dallas, Texas 75390, USA., Children\u2019s Medical Center Research Institute UoTSMC, Dallas, Texas 75390, USA., Children\u2019s Medical Center Research Institute UoTSMC, Dallas, Texas 75390, USA., Department of Pediatrics UoTSMC, Dallas, Texas 75390, USA., Nikolaus-Fiebiger-Center for Molecular Medicine UE-N, Erlangen 91054, Germany., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Harold C. Simmons Comprehensive Cancer Center UoTSMC, Dallas, Texas 75390, USA., Children\u2019s Medical Center Research Institute UoTSMC, Dallas, Texas 75390, USA., Howard Hughes Medical Institute D, Texas 75390, USA., Department of Biochemistry UoTSMC, Dallas, Texas 75390, USA., Koch Institute for Integrative Cancer Research DoB, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA., Department of Pathology MGHB, Harvard Medical School, Boston, Massachusetts 02114, USA., Department of Cell Biology UoTSMC, Dallas, Texas 75390, USA., Harold C. Simmons Comprehensive Cancer Center UoTSMC, Dallas, Texas 75390, USA (2019) MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. Genes Dev 33(17\u201318):1236\u20131251. https:\/\/doi.org\/10.1101\/gad.327056.119","journal-title":"Genes Dev"},{"key":"4936_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1417750","volume":"12","author":"J Xu","year":"2024","unstructured":"Xu J, Zheng B, Wang W, Zhou S (2024) Ferroptosis: a novel strategy to overcome chemoresistance in gynecological malignancies. Front Cell Dev Biol 12:1417750. https:\/\/doi.org\/10.3389\/fcell.2024.1417750","journal-title":"Front Cell Dev Biol"},{"key":"4936_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1739981","volume":"17","author":"J Zhang","year":"2026","unstructured":"Zhang J, Shen J, Zeng T, Gao C, Sheng B, Li J, Zeng W, Shen J, Shen C, Wang J, Wang J (2026) Targeting the NSUN2\u2013DHODH axis reverses ferroptosis resistance and oxaliplatin resistance in colorectal cancer. Front Pharmacol 17:1739981\u20131739981. https:\/\/doi.org\/10.3389\/fphar.2026.1739981","journal-title":"Front Pharmacol"},{"issue":"25","key":"4936_CR35","first-page":"e2301088","volume":"10","author":"Z Kaixuan","year":"2023","unstructured":"Kaixuan Z, Weihao L, Yue W, Zifei Z, Linjie Z, Weili Z, Yue X, Chi Z (2023) Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 10(25):e2301088\u2013e2301088","journal-title":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"key":"4936_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cells11244127","author":"Y Jin","year":"2022","unstructured":"Jin Y, Qiu J, Lu X, Li G (2022) C-MYC inhibited ferroptosis and promoted immune evasion in ovarian cancer cells through NCOA4 mediated ferritin autophagy. Cells. https:\/\/doi.org\/10.3390\/cells11244127","journal-title":"Cells"},{"issue":"10","key":"4936_CR37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s12032-023-02130-6","volume":"40","author":"M Golbashirzadeh","year":"2023","unstructured":"Golbashirzadeh M, Heidari HR, Aghamolayi AA, Fattahi Y, Talebi M, Khosroushahi AY (2023) In vitro siRNA-mediated GPX4 and AKT1 silencing in oxaliplatin resistance cancer cells induces ferroptosis and apoptosis. Medical oncology (Northwood, London, England) 40(10):279. https:\/\/doi.org\/10.1007\/s12032-023-02130-6","journal-title":"Medical oncology (Northwood, London, England)"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04936-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04936-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04936-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:20:04Z","timestamp":1786011604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04936-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4936"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04936-3","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"22 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval is not required for this study as no human or animal subjects were involved.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"84"}}